

SESSION OF 2026

**SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2218**

As Amended by House Committee on Health  
and Human Services

**Brief\***

HB 2218, as amended, would add a definition of “psilocybin” to the Uniform Controlled Substances Act (CSA) and would include certain pharmaceuticals containing psilocybin that are approved by the U.S. Food and Drug Administration (FDA) to the CSA.

The bill would define “psilocybin” as not including the pharmaceutical composition of crystalline polymorph psilocybin under any trade name approved by the FDA and would add such substance to Schedule IV of the CSA. Upon such drug’s approval by the FDA, the bill would direct the Attorney General to certify the drug product’s approval to the Secretary of State within seven days, and the Secretary of State would be required to publish the certification in the *Kansas Register*.

The bill would also make technical and conforming amendments.

**Background**

The bill was introduced by the House Committee on Health and Human Services at the request of a representative of Compass Pathways.

---

\*Supplemental notes are prepared by the Legislative Research Department and do not express legislative intent. The supplemental note and fiscal note for this bill may be accessed on the Internet at <https://klrd.gov/>

### ***House Committee on Health and Human Services***

In the House Committee hearing on February 11, 2025, **proponent** testimony was provided by a representative of Compass Pathways, who stated that the bill does not decriminalize psilocybin and is narrowly tailored to specific pharmaceuticals. The conferee stated that pharmaceutical-grade psilocybin is being studied for use in individuals with medication-resistant major depressive disorder and post-traumatic stress disorder, and the bill would make the treatment available to be prescribed to Kansas patients upon its approval by the FDA.

Written-only **neutral** testimony was provided by a representative of the State Board of Pharmacy who noted that a similar process was followed in 2018 for a different drug.

Written-only **opponent** testimony was provided by a private citizen.

No other testimony was provided.

The House Committee amended the bill to reflect technical revisions to statutory references.

### ***Fiscal Information***

According to the fiscal note prepared by the Division of the Budget on the bill, as introduced, the State Board of Pharmacy indicates that its enactment would have no fiscal effect. Any fiscal effect associated with the bill is not reflected in *The FY 2027 Governor's Budget Report*.

Uniform Controlled Substances Act; controlled substances; psilocybin; pharmaceuticals